Evaluation of Anti-inflammatory and Regenerative Efficiency of Naringin and Naringenin in Degenerated Human Nucleus Pulposus Cells: Biological and Molecular Modeling Studies

Vijaya Madhuri Devraj1,2, Satish Kumar Vemuri1,∗, Rajkiran Reddy Banala1,∗, Shravan Kumar Gunda1, Gurava Reddy AV1, Subbaiah GPV1,2

1Sunshine Medical Academy of Research and Training, Sunshine Hospitals, Secunderabad, India
2Department of Spine Surgery, Star Hospitals, Hyderabad, India
3Bioinformatics Division, Prof. G. Ram Reddy Centre for Distance Education, Osmania University, Hyderabad, India

Study Design: Development of an in vitro model for assessing the anti-inflammatory efficacies of naringin (Nar) and naringenin (NG).

Purpose: To evaluate the efficacy of natural flavonoids as therapeutic drugs against anti-inflammatory processes in the nucleus pulposus (NP) cells using in-vitro and in-silico methods.

Overview of Literature: Intervertebral disc (IVD) disease is a common cause of low back pain. Chronic inflammation and degeneration play a significant role in its etiopathology. Thus, a better understanding of anti-inflammatory agents and their role in IVD degeneration and pro-inflammatory cytokines expression is necessary for pain management and regeneration in IVD.

Methods: We performed primary cell culture of NP cells; immunocytochemistry; gene expression studies of cytokines, metalloproteases, extracellular proteins, and apoptotic markers using quantitative polymerase chain reaction and reverse transcription-polymerase chain reaction (RT-PCR); cytotoxicity assay (MTT); and molecular docking studies using AutoDock 4.2 software (Molecular Graphics Laboratory, La Jolla, CA, USA) to confirm the binding mode of proteins and synthesized complexes. We calculated the mean±standard deviation values and performed analysis of variance and t-test using SPSS ver. 17.0 (SPSS Inc., Chicago, IL, USA).

Results: Molecular docking showed that both Nar and NG bind to the selected genes of interest. Semi-quantitative RT-PCR analysis reveals differential gene expression of collagen (COL9A1, COL9A2, COL9A3, COL11A2, COMT (catechol-O-methyltransferase), and THBS2 (thrombospondin 2); up regulation of ACAN (aggrecan), COL1A1, COL11A1, interleukin (IL6), IL10, IL18R1, IL18RAP, metalloprotease (MMP)2, MMP3, MMP9, ADAMTS5 (a disintegrin and metalloproteinase with thrombospondin motifs 5), IGF1R (insulin-like growth factor type 1 receptor), SPARC (secreted protein acidic and cysteine rich), PARK2 (parkin), VDR (vitamin D receptor), and BCL2 (B-cell lymphoma 2); down regulation of IL1A, CASP3 (caspase 3), and nine genes with predetermined concentrations of Nar and NG.

Conclusions: The present study evaluated the anti-inflammatory and regenerative efficiencies of Nar and NG in degenerated human NP cells. Altered gene expressions of cytokines, metalloproteases, extracellular proteins, apoptotic genes were dose responsive. The molecular docking (in silico) studies showed effective binding of these native ligands (Nar and NG) with genes identified as potent inhibitors of inflammation. Thus, these natural flavonoids could serve as anti-inflammatory agents in the treatment of low back pain and sciatica.

Keywords: Intervertebral disc degeneration; Flavonoids; Inflammation; Nucleus pulposus; Naringin and naringenin
Introduction

Intervertebral disc degeneration (IVDD) is a common cause of lower back pain. IVDD is a complex and multifactorial disease owing to the involvement of genetic and environmental factors in its etiology. Genetic analyses have confirmed the involvement of varied genes in the etiology of IVDD and the role of single nucleotide polymorphisms in genes, such as vitamin D receptor 1 (VDR1) [1], collagen IX alleles [2,3], metalloprotease-3 (MMP-3) [4], aggrecan (ACAN) [5], transforming growth factor-b (TGFb) [6], and interleukin (IL)-1 [7] are implicated in various studies.

The structural instability of disk is mainly due to the diminished production of proteoglycans in the extracellular matrix and over expression of pro-inflammatory genes and other pathological mediators [8-10]. Current treatments available for treating degenerative disk diseases are medication, physiotherapy, and surgery that do not ensure regeneration; thus, scientists worldwide have been attempting to identify strategies that involve the use of natural extracts or phytomolecules that have the potential to control IVDD and help in the regeneration of the intervertebral disc (IVD) [11]. There are several natural compounds, such as resveratrol (3, 5, 4’-trihydroxytransstilbene), a plant phenolic compound found in the skin of grapes, blueberries, raspberries, simvastatin, atorvastatin, lovastatin, Rhizoma Drynariae, naringin (Nar), etc. that have the therapeutic potential for IVD repair. This effect is attributable to their anti-inflammatory and anti-oxidant properties that in turn enhance the proliferation of nucleus pulposus (NP) cells and downregulate the effects of tumor necrosis factor-β and MMP3 gene expression, while elevating BMP-2 (bone morphogenetic protein-2), SRY-box transcription factor 6 (SOX6), ACAN, and type II collagen protein production in NP cells in vitro, suggesting that they provide beneficial effects in IVDD treatment [12-14].

Nar and naringenin (NG) are natural flavonoids found in citrus fruits, particularly grapefruit [15,16]. Numerous studies have reported the bioactivities of Nar and its potential for treating diseases. It appears to be useful in improving cardiovascular health and has potential anticancer effects [21]. However, it is only in recent times that the health benefits of Nar and NG on disk have received much attention.

This study was designed to evaluate the regenerative and anti-inflammatory efficiency of known flavonoids Nar and NG in vitro. NP cells were isolated from the explant disk tissue and treated with different concentrations of Nar and NG individually and in combination. Our findings reveal promising effects of flavonoids in treating IVDD. However, further studies are needed before performing any clinical trials.

Materials and Methods

Nar (C_{27}H_{32}O_{14}, Cat#71162, Lot# BCBO1754) and NG (C_{15}H_{12}O_{5}, Cat#N5893, Lot# BCBR3619V) were purchased from Sigma-Aldrich (St. Louis, MO, USA). The purity of the compounds was ≥95% (high-performance liquid chromatography). Nar and NG were reconstituted in dimethyl sulfoxide (DMSO, Sigma-Aldrich) to prepare a stock solution of 2 mg/mL. Dulbecco’s modified eagle’s medium/nutrient mixture F-12 Ham (DMEM/F12, 1:1 mixture), 10% fetal bovine serum (FBS), 0.1% collagenase type I, antibiotic antimycotic solution 100× L with 10,000 units penicillin, 100 mg streptomycin and 25 μg amphotericin B per 1 mL in 0.9% saline, 0.25% trypsin-ethylenediaminetetraacetic acid, centrifuge tubes (Tarsons cat# 546041), 100 μm Nylon Mesh (Himedia, Mumbai, India; reference TCP183), and all other chemicals and reagents were analytical/culture grade reagents purchased from Himedia and Sigma-Aldrich.

1. Culture and characterization of human nucleus pulposus cells

Disk tissues were collected from disk degenerative disease patients undergoing fusion and discectomy surgeries. This
study was approved by the Institutional Ethical Committee (approval no., SS/2015/IEC127). The tissues were immediately collected in 20 mL saline supplemented with antibiotics solution and transported to the laboratory at 4°C. All the procedures were conducted in a sterile environment. Tissues were washed with phosphate-buffered saline (PBS) solution repeatedly; thereafter, the NP cells were separated by slicing the disc tissue into 1 mm$^3$ segments in a moist environment and digested with 0.1% collagenase type I at 37°C for 4 hours with intermittent shaking at 30-minute intervals. The reaction was then stopped with FBS. The digested mixture was then filtered through a sterile 100-μm nylon mesh and centrifuged at 1,500 rpm for 5 minutes to collect the cell pellet. The cells were washed in PBS solution repeatedly and re-suspended in DMEM F12 medium containing 10% FBS and antibiotics (prostate-specific antigen) and seeded with cell concentration density of 1×10$^5$/mL into a 75-cm$^2$ flask. The cells were maintained in culture flasks at 37ºC in 5% CO$_2$ atmosphere, and the culture media was changed 2–3 times a week. Flow cytometry was performed for characterization of the NP cells using CD 24 cell surface markers. On completion of characterization, the NP cells were used for further experimentation at passage 3 [19,20].

2. Treatment with naringin and naringenin

Cultured NP cells (5×10$^4$/mL) were seeded in three 12-well cell culture plates for up to 72 hours before experimentation. Various concentrations (5, 10, 20, 50, and 100 μg/mL) of Nar and NG were added to the respective group wells individually and in 1:1, 1:2, and 2:1 combinations and control cells without any drug. The NP cells were cultured for 48 hours before harvest for RNA extraction [19].

3. Immunocytochemistry of nucleus pulposus cells

Randomly selected pellets were cultured on a cover slip. Once they attained required confluency, they were fixed with 100% ethanol for 20 minutes, immunostained with primary monoclonal antibodies against collagen II and SOX6, and were incubated overnight in the dark at 4°C. Thereafter, they were counter-stained with fluorescent secondary antibody tagged to Alexa Fluor 488 for 1 hour and observed under a confocal microscope (Leica Biosystem SPE) [19,20].

4. Cell viability assay or MTT assay

Normal cells, that is, the HEK cell lines were plated in 96-well plates. Cells were treated with vehicle control or different doses of Nar and NG, and with combinations for 36 hours. We selected 10-μg dose with 1:1, 1:2, and 2:1 ratio in combination therapy to avoid unwanted cytotoxicity in normal cells. After 36 hours, cell viability was analyzed using the MTT assay as per the published protocol, and absorbance was recorded at 475 nm with reference to 660 nm [22].

5. Labeling mitochondria with MitoTracker Dye

Stock solution was prepared by dissolving the lyophilized MitoTrackerR product in high-quality, anhydrous DMSO to a final concentration of 1 mM. The reduced rosamine MitoTrackerR probes (M7511) are sensitive to oxidation and are thus protected from the light. Staining solution was prepared by diluting 1 mM MitoTrackerR stock solution to a final working concentration of 25–500 nM in appropriate buffer or growth factor for staining cells that are to be fixed and permeabilized.

Cells were grown on cover slips inside a petri dish filled with the DMEM-F12 culture medium with 10% FBS. Once we attained preferred confluency, the complete media was replaced with pre-warmed (37°C) media containing staining solution (i.e., MitoTrackerR probe) and incubated for 15–45 minutes in 5% CO$_2$ incubator. After 45 minutes of incubation, the staining solution was replaced with fresh pre-warmed media containing 3.7% formaldehyde and left at 37°C for 15 minutes. After fixation, the cells were rinsed several times with 1× PBS. The fixed cells were permeabilized by incubating in buffer-containing detergent 0.02% Triton X-100 for 10 minutes and then washed with 1× PBS. The cells were then visualized under a fluorescence microscope [23].

6. Total RNA isolation, CDNA synthesis, and polymerase chain reaction (quantitative polymerase chain reaction and quantitative reverse transcription-polymerase chain reaction)

After 48 hours, the NP cells were harvested with trypsinization, and total RNA was isolated using a Nucleopore Mini Kit (Genetix Biotech, New Delhi, India) from all 14 samples. Final RNA was eluted in 60-μL RNase free water. The concentration of RNA was determined from
Table 1. List of hypothetical genes involved in intervertebral disc disease

| No. | Genes   | Gene name                           | Sequence (5’>-3’)                          | Temperature (°C) | Functions                                                                 |
|-----|---------|-------------------------------------|-------------------------------------------|-----------------|---------------------------------------------------------------------------|
| 1   | ACAN    | Aggrecan                            | CCCCTGCTAATTTCATCGACCC                    | 64.5            | Resist compressive loads on tissue                                        |
|     |         |                                     | GACACACGGGTCCACCTTGAT                    | 62.5            |                                                                           |
| 2   | ADAMTS5 | A disintegrin and metalloproteinase | GAACATCGACCAACTCTACTCCG                  | 64.6            | Pathogenesis of human osteoarthrits                                      |
|     |         | with thrombospondin motifs 5        | CAATGCCACCGAACCACAT                    | 62.5            |                                                                           |
| 3   | BCL2    | B-cell lymphoma 2                   | GGTGAGTCTAGTGTGAGG                     | 64.5            | Pro-apoptotic, anti-apoptotic                                             |
|     |         |                                     | CCGTTCAGTACTGACATCC                     | 64.5            |                                                                           |
| 4   | CASP3   | Caspase 3                           | CATGGGAGCAATACATGACT                    | 60.8            | Apoptosis                                                                 |
|     |         |                                     | CTGTACCAGACCGAGATGCA                    | 62.6            |                                                                           |
| 5   | CASP9   | Caspase 9                           | CTCAGACCAGAGATTGCAACAC                  | 62.7            | Apoptosis                                                                 |
|     |         |                                     | GCATTTGCCCTCAAACACTCTCAA                | 60.8            |                                                                           |
| 6   | COL1A1  | Collagen I alpha 1                  | GAGGGCCAAGCAAGACAC                      | 64.5            | R rigidity and elasticity                                                 |
|     |         |                                     | GAGGGCCAAGCAAGACAC                      | 64.5            | Delay onset of osteoarthritis                                             |
| 7   | COL9A1  | Collagen IX alpha 1                 | GCCAGTAGAGGAGAATTGACC                   | 64.6            |                                                                           |
|     |         |                                     | GTTCACCGACTACACCGCT                     | 64.5            |                                                                           |
| 8   | COL9A2  | Collagen IX alpha 2                 | CTCCGCTCTGGGCGAGATTAG                   | 64.5            | Cartilage and bone ossification                                          |
|     |         |                                     | GCCCATTGTCCACCGCTCGA                    | 62.3            |                                                                           |
| 9   | COL9A3  | Collagen IX alpha 3                 | GTGGATGTTGCTAGTGGGACG                   | 64.5            | Cartilage and bone ossification                                          |
|     |         |                                     | GGGCGATCATGGGGCTCG                      | 64.5            |                                                                           |
| 10  | COL11A1 | Collagen XI alpha 1                 | TAAACATCGCTAGCAGAAGTGA                  | 62.6            | Ossification, prevent disc bulging                                        |
|     |         |                                     | CGGTATCCAGTGTAGTAACA                    | 61.0            |                                                                           |
| 11  | COL11A2 | Collagen XI alpha 2                 | TCTTTGGGCGGCCGATATTCTGG                 | 62.6            | Cartilage ossification                                                   |
|     |         |                                     | TGGGGTCTCGATTGGTGGG                     | 62.6            |                                                                           |
| 12  | COMT    | Catechol-O-methyltransferase         | GAAGGGAAGCAGTGTACTCTG                   | 64.5            | Inactivation of the catecholamine neurotransmitters                      |
|     |         |                                     | CAGGAACGATGATGATGATGTG                  | 62.7            |                                                                           |
| 13  | IGF1R   | Insulin-like growth factor type 1    | AGGATATGTCGACCCCTACAACCTCG             | 61.0            | Hypertrophy of muscle and tissue                                          |
|     |         | receptor                            | GAGGAGGACAGAGATCTGACTGT                 | 64.5            |                                                                           |
|     |         |                                     | CAGGAACGACTAGATGTGTGTG                  | 62.7            |                                                                           |
| 14  | IL1A    | Interleukin 1a                       | AGATGCTGAGATACACCCAAACC                 | 62.8            | Inflammatory cytokine                                                     |
|     |         |                                     | CCAAGGCACACCCAGCTAGTC                   | 62.5            |                                                                           |
| 15  | IL6     | Interleukin 6                        | ACTCACCTTCTCAGAAGAATTTG                 | 61.0            | Pro-inflammatory cytokine Anti-inflammatory myokine                        |
|     |         |                                     | CCACTTTGAGATAGCTGTG                      | 62.8            |                                                                           |
| 16  | IL10    | Interleukin 10                       | GACCTTAAGGTTAACCTGGGTGG                  | 62.8            | Anti-inflammatory cytokine                                                |
|     |         |                                     | TCACATGCCCTGATGTCGTG                    | 62.6            |                                                                           |
| 17  | IL18R1  | Interleukin 18 receptor 1            | CCTGACCTCTGGGTTGCTTA                    | 62.6            | Pro-inflammatory Interleukin-18-mediated signaling pathway                |
|     |         |                                     | CTCATGTGCAAGTGAACACGA                    | 60.6            |                                                                           |
| 18  | IL18RAP | Interleukin 18 receptor accessory    | ACCTGCCCCTCAGGAGTAGA                    | 62.6            | Cell-mediated immunity                                                    |
|     |         | protein                             | CCCCTGGGTCAAAGGATGGA                    | 62.5            |                                                                           |

(Continued to the next page)
the optical density of the sample measured at 260 nm using nanodrop. The extracted RNA samples were analyzed for the expression of 25 genes: COL9A1, COL9A2, COL9A3, COL11A2, catechol-O-methyltransferase (COMT), THBS2 (thrombospondin 2), ACAN, COL1A1, COL11A1, IL6, IL10, IL18R1, IL18RAP, MMP2, MMP3, MMP9, ADAMTS5 (a disintegrin and metalloproteinase with thrombospondin motifs 5), insulin-like growth factor type 1 receptor (IGF1R), secreted protein acidic and cysteine rich (SPARC), parkin (PARK2), IL1A, CASP3, CASP9, and glyceraldehyde 3-phosphate dehydrogenase (GAPDH) as a housekeeping gene. cDNA synthesis was conducted using a Verso cDNA Synthesis Kit (Thermo Fischer Scientific, Waltham, MA, USA), and the template DNA was used for gene-specific polymerase chain reaction (PCR, SimpliAmp Thermal Cycler, Applied Biosystems; Thermo Fischer Scientific) and reverse transcription-polymerase chain reaction (RT-PCR) (QuantStudio 5, Applied Biosystems; Thermo Fischer Scientific). PCR and RT-PCR reactions were performed as per the manufacturer’s instructions. Primers used in this study were designed using the online “Primer3” program (http://bioinfo.ut.ee/primer3-0.4.0/primer3/); the details of the primers are listed in Table 1. All PCR products were visualized on 1.5% agarose gel with 0.5 mg/mL ethidium bromide. Photographs were taken using the gel documentation system (E Gel Imager; Life Technologies, Carlsbad, CA, USA) [22].

7. Molecular docking studies

Molecular docking studies were performed to explain the binding mode of proteins and ligands. All the compounds were docked using the AutoDock 4.2 software (Molecular Graphics Laboratory, La Jolla, CA, USA). All the molecules were docked individually in AutoDock 4.2 [24-26]. The modeled three-dimensional structure of all the proteins was imported to AutoDock 4.2 and structurally optimized by adding hydrogens to the protein allocated with kollman charges. After adding the hydrogens, the model was saved in the PDBQT format; thereafter, ligands were prepared by optimizing the torsion angles and saved in the PDBQT format. The potential binding site for all the proteins were selected by using PDBSUM (http://www.ebi.ac.uk/pdbsum) [24-27]. A grid was generated to identify the xyz coordinates around the binding site of the proteins individually. Lamarckian genetic algorithm (LGA) was selected for freezing docking and default parameters used in AutoDock 4.2.
8. Statistical analyses

All the individual results are expressed as mean±standard deviation values. The mean values of the grouped results were tested using two-way analysis of variance (ANOVA) test, evaluated with the statistical packages SPSS ver. 17.0 (SPSS Inc., Chicago, IL, USA). A p-value <0.05 was accepted as statistically significant.

9. Informed consent

This study was approved by the Institutional Ethical Board of the Sunshine Hospital and Research Centre (approval no., SS/2015/IEC127). Written informed consent was sought after providing complete study description to the subjects.

Results

1. Culture of the human nucleus pulposus cells

NP cells were successfully isolated from the degenerated IVD from the lumbar spine and were further cultured for P0–P3 generations, propagated, expanded, and characterized after the third passage (Figs. 1, 2).

2. Treatment with naringin and naringenin

Cultured NP cells (5×10^4 cells/mL) were seeded in 12-well plates and incubated for 72 hours before the experiment. Different concentrations of Nar and NG (5, 10, 20, 50, and 100 μg/mL) were added to wells in duplicates, and combinations of both were added in 1:1 (10:10 and 20:20 μg/mL), 1:2 (10:20 μg/mL), and 2:1 (20:10 μg/mL) ratios to the respective group wells in duplicate (Fig. 3). In comparison with the individual treatments, the combinatorial treatments of Nar-NG (1:2 and 2:1 ratios) did not show much significance; however, the dosages of Nar, NG (10–50 μg/mL) individually and in combination (1:1 ratio), resulted in a significant increase as confirmed on post-PCR gel images at particular concentrations. However, no cytotoxicity was observed at 100 μg/mL, and the concentration of 20 μg/mL Nar and NG appeared most effective and was found to be the optimum dose for promoting cell proliferation.
3. Cytotoxicity studies-MTT assay

We performed an MTT assay study for assessing the proliferation efficiency in the HEK-293 cell line in the presence of Nar and NG individually and in combination after 36 hours of exposure (Fig. 4). However, the results of the MTT assay suggest that Nar or NG do not induce any cytotoxicity in the HEK-293 (normal) cell line, and the cells were proliferating normally when treated with similar dosages under our study conditions.

4. Immunocytochemistry for nucleus pulposus cells

After treatment with 20 μg/mL Nar and NG and their combination in a 1:1 ratio, the NP cells were immunostained with primary monoclonal antibodies collagen II.
and SOX2 and were then counter-stained with fluorescent secondary antibody Alexa-488 mounted with DAPI (4', 6-diamidino-2-phenylindole) nuclear stain. It showed higher expression in the cells treated with Nar and NG compared than in the untreated control sample (Fig. 5).

5. Labeling mitochondria with Mitotracker dye

After treatment with Nar and NG, the cells were loaded with Mitotracker Green FM for mitochondria staining; representative images of mitochondrial morphology are shown in Fig. 6. Thus, mitochondrial morphological changes were analyzed with and without the drug. Mitochondria in control sample, expression was reduced under oxidative stress condition in cells, suggesting disruption and depolarization of mitochondria without drug whereas in drug-treated cells it showed over expression.

6. Effect of naringin and naringenin on gene expression assessed using reverse transcription-polymerase chain reaction

Real-time PCR followed by gel electrophoresis was used to assess the changes in the expression of 26 genes (i.e., ACAN, collagens, interleukins, MMP, ADAMTS, etc.) constituting the markers for disk and inflammation (Fig. 7). All the samples considered for RT-PCR had five concentrations each of Nar and NG (10, 25, 50, 100, and 200 μg/mL) and were used in the ratios of 1:1, 1:2, and 2:1 of both Nar and NG as combination drugs. Cells that were not given any treatment were considered as controls. The subsequent section includes an overview of the genes studied and their expression (upregulation and downregulation) as mentioned in Table 2. Further, we observed changes in the gene expression of similar genes with different drug concentrations.

GAPDH was used as a housekeeping gene. The dose-dependent Nar and NG increased the expression of discogenic regeneration markers, such as collagen and ACAN.
Maximal expression was observed at a concentration of 20 μg/mL, and the combination usage of 1:2 concentration showed dramatically increased gene expression. However, treatment with Nar and NG showed effectiveness toward minimal expression of inflammatory markers, such as interleukins, caspase, and MMPs (Fig. 7).

7. Heat map effect

Grouped double gradient heat map was done using two-way ANOVA. The table of rows and columns factor of untreated (control) and treated (drug) versus means of various genes (expression by RT-PCR) showed a p-value with statistical significance (p=0.0033, 0.0009). Fig. 8 shows the heat map of the grouped data (Fig. 8A) with two rows and 25 columns corresponding to 25 genes (treated and untreated) (Fig. 8B) 25 genes with respect to various dosages; smallest value coded in green show higher expression, and the largest values in red show lower expression. Two-way ANOVA showed a significant p-value for both, the row and column factors with p-value <0.001. Genes were expressed deferentially in the control and treated groups, showing either up regulation or down regulation for most genes, while other genes have shown a trend toward marginal or neutral expression levels.

8. Molecular docking interactions of naringin and naringenin

Docking of NG and Nar compounds into the binding site of all the proteins was performed to estimate the binding affinity of the complex. It is a significant part of the structure-based drug design process. It is an open-source software for drug discovery and molecular docking. The structural interactions between Protein Data Bank (PDB) with two inhibitors were docked separately. Docking studies are commonly performed for predicting the binding affinities of proteins and the binding energies of their ligands. X, Y, and Z coordinates of all the PDB’s were selected by using SPDBV (http://www.expasy.org/spdbv/). Autodock 4.2 uses binding free energy assessment to assign the best binding conformation.

A molecular docking study was performed by using AutoDock 4.2. In this docking process, the protein is set
as rigid and the ligand as flexible. AutoDock uses the LGA to search for the best conformation with reference to the minimum binding energy (kcal/mol) and hydrogen bond distance between the protein and the ligand.

Molecular docking is the most extensively used method for the calculation of protein-ligand interactions. It is an efficient method to predict the potential ligand interactions. In this study, the native ligands (NG and Nar) were identified as potent different cancer inhibitors. AutoDock 4.2 uses binding free energy assessment to assign the best binding conformation. Dockings of the NG and Nar compounds are summarized in Tables 2 and 3, respectively. Both the derivatives selected for molecular docking have some collective structural features. The comparison of free energies corresponding to the binding of title compounds with target protein reveals that maximum of the compounds interact with the receptor. Almost all molecules exhibited lower free energy values, indicating more thermodynamically favored interaction.

9. Naringenin

Molecular interaction between NG with different cancer targets, calculated the docking score. The protein was downloaded from PDB for docking analysis. It was found that NG made Hydrogen bond with the amino acid residue Pro221 and Thr215 of PDB ID: 1D8M, a MMP3 target with binding energy of −8.56 kcal/mol. It also shows a hydrogen bond with Ala136 and Val117 with binding energy of −7.97 kcal/mol a MMP2 protein.

Similarly, we docked with the following targets VDR, CASP9, COL1A1, COMT, ADAMTS5, MMP9, CASP9, PARK2, IGFR1R, IL18RAP, ACAN, IL181, IL6, IL10, SPARC, IL1A, and BCL2. Nar was docked against all these targets. Among these, MMP3, MMP2, VDR, CASP9, COL1A1, and COMT targets show the best binding energy of >−7.0 kcal/mol. Except BCL2, all the other targets showed good binding energy and interactions.

10. Naringin

Molecular interaction between Nar with different cancer targets, calculated the docking score. The protein was downloaded from PDB for docking analysis. Nar created a hydrogen bond with the amino acid residue Leu295, Asn297, and Asn293 of PDB ID: 2OJ9, an IGFR1R target with a binding energy of −7.1 kcal/mol. It also showed a hydrogen bond with Ala136 and Leu117 with binding energy of −7.0 kcal/mol and a MMP2 protein. Nar also showed a hydrogen bond with Ala136 and Leu117 with binding energy of −7.97 kcal/mol and a MMP2 protein.

Similarly, we docked with the following targets VDR, CASP9, COL1A1, COMT, ADAMTS5, MMP9, CASP9, PARK2, IGFR1R, IL18RAP, ACAN, IL181, IL6, IL10, SPARC, IL1A, and BCL2. Nar was docked against all these targets. Among these, MMP3, MMP2, VDR, CASP9, COL1A1, and COMT targets show the best binding energy of >−7.0 kcal/mol. Except BCL2, all the other targets showed good binding energy and interactions.
energy of $-5.0$, and other targets showed less binding energy.

From the docking simulation, we observed free energy charge of binding for the protein-ligand complex. A possible explanation may be that the radiographical structure of the protein from crystals differs from that of the aqueous system. The total energy was calculated for both the compounds against different targets shown in the Tables 2 and 3. Therefore, it can be concluded that the interaction of Nar and NG with the corresponding targets is hydrophobic interactions in nature. Molecular docking indicated that the distance of hydrogen bonding between the ligand and the protein, respectively.

AutoDock 4.2 uses binding free energy assessment to assign the best binding conformation. Experimental activities and predicted values by LGA. Dockings of the Nar and NG compounds are summarized in Table 2 and Table 3, respectively.

**Table 2. Molecular docking interactions of naringin with their binding energy**

| Gene name | PDB ID | Interacting amino acids | Grid X-Y-Z coordinates | Binding energy $\Delta G$ (kcal/mol) | Dissociation constant (kl) ($\mu$M) |
|-----------|--------|-------------------------|------------------------|--------------------------------------|-----------------------------------|
| IL10      | 2ILK   | Lys117, Ser118, Lys119  | 22.601, 40.659, 43.545  | -4.16                                | 889.49                            |
| COL1A1    | 3EJH   | Arg552, Lys554, Arg967  | -23.600, 17.974, -4.216 | -3.15                                | 4.89 mM                           |
| BCL2      | 4A03   | Trp103, Asn151(2), Val101 | -28.353, 15.626, -21.45 | -4.42                                | 572.84                            |
| CASP3     | 2C20   | Asp2(2), Trp214, Asn208, Glu146 | 37.644, 25.480, 23.831 | -5.65                                | 72.16                             |
| CASP9     | 2AR9   | -                       | 18.979, 34.366, -14.505 | -5.67                                | 69.52                             |
| COMT      | 3A7E   | Asp44, Tyr200, Arg201   | -20.385, 14.881, 13.606 | 303.56                               | -                                 |
| IGFR1R    | 2OJ9   | Leu295, Asn297, Asn293  | 1.028, -2.661, 12.226  | -7.1                                 | 6.2                               |
| IL1A      | 1IRA   | Lys109(2), Lys111, Glu94 | 46.907, 7.065, 57.268  | -3.75                                | 1.78 mM                           |
| IL6       | 1ALU   | Gly77, Ser76            | -17.612, -13.109, 7.459 | -3.53                                | 2.59 mM                           |
| IL18RAP   | 3W04   | Glu32, Thr21, Glu22    | -45.056, -2.620, -25.058 | -5.95                                | 43.53                             |
| IL181     | 4R6U   | His1030, Lys1120, Cys1029, Glu995 | 274.429, -35.631, 115.918 | -3.74                                | 1.83 mM                           |
| MMP2      | 1H0V   | Ala136, Leu83          | 7.840, 20.181, 15.297  | -7.09                                | 6.33                              |
| MMP3      | 4D8M   | Ala167(3)               | 66.413, 77.078, 37.874  | -5.67                                | 69.5                              |
| MMP9      | 1GKD   | Asp410, Ala191, His411 | 6.214, 47.409, -17.281  | -5.42                                | 107.12                            |
| PARK2     | 5C1Z   | Lys161                 | -21.821, 23.775, 18.419 | -3.74                                | 1.8 mM                            |
| SPARC     | 2V53   | Ile226(3), Leu266      | 12.436, 30.887, 29.607  | -3.65                                | 2.1                               |
| VDR       | 5GT4   | Lys240, Gln239        | -9.061, -10.888, 29.360 | -3.87                                | 1.45                              |
| ACAN      | 4MD4   | Lys111, Glu88         | 26.646, 30.740, -5.433  | -5.07                                | 191.53                            |
| ADAMTS5   | 3HYG   | Val384, Ala382, His420, Thr378, Ser419 | 15.531, -1.503, 1.836 | -5.28                                | 134.02                            |

PDB, Protein Data Bank; IL, interleukin; COL1A1, collagen I alpha 1; BCL2, B-cell lymphoma 2; CASP, caspase; COMT, catechol-O-methyltransferase; IGF1R, insulin-like growth factor type 1 receptor; MMP, matrix metalloproteinase; PARK2, parkin; SPARC, secreted protein acidic and cysteine rich; VDR, vitamin D receptor; ACAN, aggrecan; ADAMTS5, a disintegrin and metalloproteinase with thrombospondin motifs 5.

**Discussion**

The present study systematically studied the effects of Nar and NG on explant disk tissue and evaluated their potency in alleviating the disease condition by enhanced NP cells proliferation in the disk tissue. Further, the mechanisms of action of Nar and NG in IVDD were understood by the specific gene expression among variably considered genes for our research. Based on the above findings and our knowledge on Nar and NG as important natural drugs available, we decided to characterize the ratio of Nar/NG on NP cells regeneration in patients with IVDD.

Characterization of the NP cells was performed using flow cytometry (i.e., using CD24 marker). Immunocytochemistry studies were also performed where the NP cells were characterized subsequently using type II collagen and SOX2 antibody counter-stained with DAPI nuclear stain, showing higher expression in cells treated with Nar and NG than in untreated cells (Figs. 2, 5). Our results
showed that Nar and NG appear to enhance the proliferation of human NP cells in a dose-dependent manner independently (i.e., 5, 10, 20, 50, and 100 μg/mL). All these concentrations showed varied effectiveness with the type of gene involved, with a majority being noticed as having beneficial effects. The concentration of 5 μg/mL was too low to show its effect in cells and that of 100 μg/mL was too high and caused cell apoptosis; thus, the optimum dosages of 10 μg/mL and 50 μg/mL had the highest influence on cell proliferation (Fig. 4).

Mitochondrial morphological changes were also analyzed with and without drug treatment. Mitochondrial expression in the control sample was reduced under oxidative stress conditions in the cells, suggesting disruption and depolarization of the mitochondria without drug; however, the mitochondria were over-expressed in the drug-treated cells (Fig. 6). Up regulation of discogenic markers and down regulation of inflammatory markers was noticed in the NP cells. We observed that treatment with these drugs effectively diminished the inflammatory response.

| Gene name | PDB ID | Interacting amino acids | Grid X-Y-Z coordinates | Binding energy ΔG (kcal/mol) | Dissociation constant (kl) (µM) |
|-----------|--------|-------------------------|------------------------|-----------------------------|---------------------------------|
| IL10      | 2ILK   | Arg110, Lys117          | 22.601, 40.659, 43.545  | -5.14                        | 171.19                          |
| COL1A1    | 3EJH   | Tyr525, Leu963          | -23.600, 17.974, -4.216 | -7.19                        | 5.38                            |
| BCL2      | 4A03   | Asp150, Glu159          | -28.353, 15.626, -21.45  | -4.44                        | 553.93                          |
| CASP3     | 2CZO   | Asn208, Trp214, Glu248, Asp2 | 37.644, 25.480, 23.831  | -6.07                        | 78.29                           |
| CASP9     | 2AR9   | -                       | 18.979, 34.366, -14.505  | -7.79                        | 2.06                            |
| COMT      | 3A7E   | Arg201, Val42           | -20.385, 14.881, 13.606  | -7.16                        | 5.63                            |
| IGFR1R    | 2OJ9   | His1030, Asn1028, Thr998| 1.028, -2.661, 12.226    | -5.87                        | 50.15                           |
| IL1A      | 1IRA   | Leu35, Glu20            | 46.907, 7.065, 57.268    | -5.05                        | 72.15                           |
| IL6       | 1AU    | -                       | -17.612, -13.109, 7.459  | -5.28                        | 134.36                          |
| IL18RAP   | 3W04   | Arg113, Glu122, Arg123  | -45.056, -2.620, -25.058 | -5.86                        | 50.63                           |
| IL18      | 4R6U   | Gly252, Leu295          | 274.429, -35.631, 115.918| -5.33                        | 124.08                          |
| MMP2      | 1D8M   | Ala136, Val117          | 7.840, 20.181, 15.297    | -7.97                        | 1.45                            |
| MMP3      | 108M   | Pro221, Thr215          | 66.413, 77.078, 37.874   | -8.56                        | 535.28 nM                       |
| MMP9      | 1GKD   | Leu114, Asp410, Ala191  | 6.214, 47.409, -17.281   | -6.62                        | 14.13                           |
| PARK2     | 5C1Z   | Arg163, Thr83, Val456   | -21.821, 23.775, 18.419  | -5.99                        | 170.24                          |
| SPARC     | 2V53   | Lys282, Asp222, Asp267  | 12.436, 30.887, 29.607   | -5.14                        | 170.24                          |
| VDR       | 5Q14   | Asp144, Ser278, Thr236  | -9.061, -10.888, 29.360  | -7.80                        | 1.91                            |
| ACAN      | 4MD4   | -                       | 26.646, 30.740, -5.433   | -5.71                        | 65.01                           |
| ADAMTS5   | 3HYG   | Ala382, Ser315          | 15.531, -1.503, 1.836    | -6.71                        | 12.08                           |

PDB, Protein Data Bank; IL, interleukin; COL1A1, collagen I alpha 1; BCL2, B-cell lymphoma 2; CASP, caspase; COMT, catechol-O-methyltransferase; IGF1R, insulin-like growth factor type 1 receptor; MMP, matrix metalloproteinase; PARK2, parkin; SPARC, secreted protein acidic and cysteine rich; VDR, vitamin D receptor; ACAN, aggrecan; ADAMTS5, a disintegrin and metalloproteinase with thrombospondin motifs 5.
cytokine expression individually and in combination. Further, the expression of elevated disk markers was obvious after Nar and NG treatment, indicating repair and regeneration of the NP cells in the disk tissue (Fig. 7).
RT-PCR results showed that the genes responsible for pro-inflammation, such as interleukins, caspases, and MMPs, were down regulated, while those with functions of discogenesis, bone repair, and collagen formation (such as collagen and ACAN) were well expressed, suggesting an overall beneficial effect of these flavonoids (Fig. 8A, B).

We further studied molecular docking to confirm the binding efficiency and dissociation constants for both Nar and NG. This is important because computational and bioinformatics tools are the most extensively used methods for calculating protein-ligand interactions [26]. This is an efficient method to predict potential ligand interactions. In this study, the native ligands (Nar and NG) were identified as potent inhibitors of inflammation. Both the derivatives selected for molecular docking have some collective structural features. The comparison of free energies corresponding to the binding of title compounds with the target protein reveals that most of the compounds interact with the receptor. Almost all the molecules exhibited lower free energy values, indicating more thermodynamically favored interactions (Figs. 9, 10).

Conclusions

Our study revealed that the use of these flavonoids to inhibit the function of inflammatory cytokines using virtual screening is an important consideration. In contrast, inhibitory constant energy and energy binding levels of certain disc markers suggested a repair mechanism to regenerate NP cells.

The present study clearly shows that citrus flavonoids are useful for improvement of inter vertebral disc properties. Further, it is noted that elevated discogenic markers expression was evident after Nar and NG treatment that indicates repair and regeneration of the NP cells in the disc tissue. We studied the expression profile of various genes using RT-PCR that revealed deferential up-regulated and down-regulated genes. The binding efficiency of these genes to flavonoids, such as Nar and NG, were confirmed in molecular docking studies that identified them as having potent anti-inflammatory properties that improved their clinical treatment efficacy. Thus, they should be recommended for use in the treatment of patients with lumbar problems.

Conflict of Interest

No potential conflict of interest relevant to this article was reported.

Acknowledgments

We wish to extend our sincere thanks to Dr Adarsh Reddy A and Dr Kushal H from Sunshine Medical Academy of Research and Training, Sunshine Hospitals and Star Hospitals for their continuous support. Special thanks to Dr Paul Marx for his support during the study.

References

1. Li Y, Zhu J, Gao C, Peng B. Vitamin D receptor (VDR) genetic polymorphisms associated with intervertebral disc degeneration. J Genet Genomics 2015;42:135-40.
2. Annunen S, Paassilta P, Lohiniva J, et al. An allele of COL9A2 associated with intervertebral disc disease. Science 1999;285:409-12.
3. Seki S, Kawaguchi Y, Mori M, et al. Association study of COL9A2 with lumbar disc disease in the Japanese population. J Hum Genet 2006;51:1063-7.
4. Ito S, Kimura K, Haneda M, Ishida Y, Sawada M, Isobe K. Induction of matrix metalloproteinases (MMP3, MMP12 and MMP13) expression in the microglia by amyloid-beta stimulation via the PI3K/Akt pathway. Exp Gerontol 2007;42:532-7.
5. Mashayekhi F, Shafee G, Kazemi M, Dolati P. Lumbar disk degeneration disease and aggrecan gene polymorphism in northern Iran. Biochem Genet 2010;48:684-9.
6. Jin H, Shen J, Wang B, Wang M, Shu B, Chen D. TGF-β signaling plays an essential role in the growth and maintenance of intervertebral disc tissue. FEBS Lett 2011;585:1209-15.
7. Karppinen J, Solovieva S, Luoma K, Raininko R, Leino-Arjas P, Riihimaki H. Modic changes and interleukin 1 gene locus polymorphisms in occupational cohort of middle-aged men. Eur Spine J 2009;18:1963-70.
8. Schwarzer AC, April CN, Derby R, Fortin J, Kine G, Bogduk N. The prevalence and clinical features of internal disc disruption in patients with chronic low back pain. Spine (Phila Pa 1976) 1995;20:1878-83.
9. Battie MC, Videman T. Lumbar disc degeneration:
epidemiology and genetics. J Bone Joint Surg Am 2006;88 Suppl 2:3-9.
10. Anderson DG, Tannoury C. Molecular pathogenic factors in symptomatic disc degeneration. Spine J 2005;5(6 Suppl):260S-266S.
11. Le Maitre CL, Pockert A, Buttle DJ, Freemont AJ, Hoyland JA. Matrix synthesis and degradation in human intervertebral disc degeneration. Biochem Soc Trans 2007;35(Pt 4):652-5.
12. Erlund I, Meririnne E, Alfthan G, Aro A. Plasma kinetics and urinary excretion of the flavanones naringenin and hesperetin in humans after ingestion of orange juice and grapefruit juice. J Nutr 2001;131:235-41.
13. Kanno S, Tomizawa A, Hiura T, et al. Inhibitory effects of naringenin on tumor growth in human cancer cell lines and sarcoma S-180-implanted mice. Biol Pharm Bull 2005;28:527-30.
14. Chanet A, Milenkovic D, Deval C, et al. Naringin, the major grapefruit flavonoid, specifically affects atherosclerosis development in diet-induced hypercholesterolemia in mice. J Nutr Biochem 2012;23:469-77.
15. Kuntz S, Wenzel U, Daniel H. Comparative analysis of the effects of flavonoids on proliferation, cytotoxicity, and apoptosis in human colon cancer cell lines. Eur J Nutr 1999;38:133-42.
16. Duan YJ, Mu G, Kang Z, Zhang G. Treatment of intervertebral disc herniation patients 115 with self made low back pain capsule. Clin J Tradit Chin Med 2005;1:1901.
17. Lu Y, Zhang C, Bucheli P, Wei D. Citrus flavonoids in fruit and traditional Chinese medicinal food ingredients in China. Plant Foods Hum Nutr 2006;61:57-65.
18. Benavente-Garcia A, Castillo J. Update on uses and properties of citrus flavonoids: new findings in anticancer, cardiovascular, and anti-inflammatory activity. J Agric Food Chem 2008;56:6185-205.
19. Kluba T, Niemeyer T, Gaissmaier C, Grunder T. Human anulus fibrosis and nucleus pulposus cells of the intervertebral disc: effect of degeneration and culture system on cell phenotype. Spine (Phila Pa 1976) 2005;30:2743-8.
20. Li N, Whitaker C, Xu Z, Heggeness M, Yang SY. Therapeutic effects of naringin on degenerative human nucleus pulposus cells for discogenic low back pain. Spine J 2016;16:1231-7.
21. Baskari S, Govatati S, Madhuri V, et al. Influence of autocrine growth hormone on NF-κB activation leading to epithelial-mesenchymal transition of mammary carcinoma. Tumour Biol 2017;39:1010428317719121.
22. Vemuri SK, Banala RR, Sudhaiah GP, Srivastava SK, Reddy AG, Malavili T. Anti-cancer potential of a mix of natural extracts of turmeric, ginger and garlic: a cell-based study. Egypt J Basic Appl Sci 2017;4:332-44.
23. Keij JF, Bell-Prince C, Steinkamp JA. Staining of mitochondrial membranes with 10-nonyl acridine orange, MitoFluor Green, and MitoTracker Green is affected by mitochondrial membrane potential altering drugs. Cytometry 2000;39:203-16.
24. Laskowski RA. PDbusy new things. Nucleic Acids Res 2009;37(Database issue):D355-9.
25. Morris GM, Huey R, Lindstrom W, et al. AutoDock4 and AutoDockTools4: automated docking with selective receptor flexibility. J Comput Chem 2009;30:2785-91.
26. Osghuthorpe DJ, Sherman W, Hagler AT. Generation of receptor structural ensembles for virtual screening using binding site shape analysis and clustering. Chem Biol Drug Des 2012;80:182-93.
27. Goodsell DS, Olson AJ. Automated docking of substrates to proteins by simulated annealing. Proteins 1990;8:195-202.